HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vieregge, A. Articles by Vieregge, P. Search for Related Content PubMed PubMed Citation Articles by Vieregge, A. Articles by Vieregge, P. Related Collections Parkinson's disease/Parkinsonism Clinical trials Randomized controlled (CONSORT agreement)

Transdermal nicotine in PD

A randomized, double-blind, placebo-controlled study

From the Department of Neurology, University Hospital of Lübeck, Germany.

Address correspondence and reprint requests to Prof. P. Vieregge, Department of Neurology, Klinikum Lippe-Lemgo, Rintelner Str. 85, D-32657 Lemgo, Germany; e-mail: peter.vieregge{at}klinikum-lippe.de

Background:— An inverse association between cigarette smoking and the risk of idiopathic PD has been found in many epidemiologic studies. The therapeutic and possible neuroprotective effects of nicotine formulations on parkinsonian symptoms are controversial.

Methods:— In a 12-week, randomized, double-blind, placebo-controlled trial, the efficacy and tolerability of transdermal nicotine patches as an add-on treatment for cardinal symptoms were evaluated in 32 nonsmoking patients with PD. After a 1-week run-in phase, patients were randomized to receive nicotine patches (containing 17.5 mg nicotine in the first and 35.0 mg nicotine in the second and third weeks) or identically appearing placebo patches. After this treatment, 3 weeks without patch application followed. The same blinded examiner assessed the patients with the Columbia University Rating Scale, the Webster scale, the Schwab–England scale, a timed walking test, with an instrumental test for fine motor skills and hand tremor, and with the Hamilton Depression Scale.

Results:— No significant drug effects between both groups were observed in any of the scores and quantitative tests. Side effects were mild and comparable in frequency between both groups.

Conclusions:— With the dosage and the period of treatment chosen, transdermal nicotine patches are not effective as an add-on treatment for symptoms of PD.

This article has been cited by other articles:

				B. Ritz, A. Ascherio, H. Checkoway, K. S. Marder, L. M. Nelson, W. A. Rocca, G. W. Ross, D. Strickland, S. K. Van Den Eeden, and J. Gorell Pooled Analysis of Tobacco Use and Risk of Parkinson Disease Arch Neurol, July 1, 2007; 64(7): 990 - 997. [Abstract] [Full Text] [PDF]

				T. Bordia, N. Parameswaran, H. Fan, J. W. Langston, J. M. McIntosh, and M. Quik Partial Recovery of Striatal Nicotinic Receptors in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-Lesioned Monkeys with Chronic Oral Nicotine J. Pharmacol. Exp. Ther., October 1, 2006; 319(1): 285 - 292. [Abstract] [Full Text] [PDF]

				M. Quik, L. Chen, N. Parameswaran, X. Xie, J. W. Langston, and S. E. McCallum Chronic oral nicotine normalizes dopaminergic function and synaptic plasticity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates. J. Neurosci., April 26, 2006; 26(17): 4681 - 4689. [Abstract] [Full Text] [PDF]

				The Parkinson Study Group Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease Neurology, February 14, 2006; 66(3): 408 - 410. [Abstract] [Full Text] [PDF]

				M. Quik and J. M. McIntosh Striatal {alpha}6* Nicotinic Acetylcholine Receptors: Potential Targets for Parkinson's Disease Therapy J. Pharmacol. Exp. Ther., February 1, 2006; 316(2): 481 - 489. [Abstract] [Full Text] [PDF]

				N. M. Warren, M. A. Piggott, E. K. Perry, and D. J. Burn Cholinergic systems in progressive supranuclear palsy Brain, February 1, 2005; 128(2): 239 - 249. [Abstract] [Full Text] [PDF]

				K. A. Sacco, K. L. Bannon, and T. P. George Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders J Psychopharmacol, December 1, 2004; 18(4): 457 - 474. [Abstract] [PDF]

				D. Aarsland, U. P. Mosimann, and I. G. McKeith Role of Cholinesterase Inhibitors in Parkinson's Disease and dementia with Lewy Bodies J Geriatr Psychiatry Neurol, September 1, 2004; 17(3): 164 - 171. [Abstract] [PDF]

				F.-M. Zhou, C. Wilson, and J. A. Dani Muscarinic and Nicotinic Cholinergic Mechanisms in the Mesostriatal Dopamine Systems Neuroscientist, February 1, 2003; 9(1): 23 - 36. [Abstract] [PDF]

				J. Jacobi, J. J. Jang, U. Sundram, H. Dayoub, L. F. Fajardo, and J. P. Cooke Nicotine Accelerates Angiogenesis and Wound Healing in Genetically Diabetic Mice Am. J. Pathol., July 1, 2002; 161(1): 97 - 104. [Abstract] [Full Text] [PDF]

				M. F. Allam, A. Vieregge, M. Sieberer, H. Jacobs, J.M. Hagenah, and P. Vieregge Transdermal nicotine in PD: A randomized, double-blind, placebo-controlled study Neurology, April 9, 2002; 58(7): 1133 - 1133. [Full Text] [PDF]

Correspondence: